9 July 2018
Sahlgrenska University hospital (SU) and the ethics council has now approved the continuation of treatment of new patients with osseointegrerade implants for protesförankring.
«We will call the patients who were on the waiting list for the operation until the autumn, and to offer patients in the reception for the förstagångsbedömningar.», says Carina Reinholdt, operations Manager and Consultant at SU C. A. R. E. (Center for Advanced Reconstruction of Extremities).
As previously reported, the SU stopped the new operations with the osseointegrerade implants, which announced the company 30 January 2018.
The information in this press release is such information that Integrum AB (publ) is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted according to the following contact person in the government, for publication on 9 July 2018 there is a 0830 CEST.
About Integrum AB
Integrum is a medical device company that develops and markets systems for skelettförankrade dentures. With over 400 operations carried out in twelve countries and having worked in the market for almost 20 years, believes the Company will have a leading position in the field. Integrums innovative called opra Implant System helps to improve the quality of life for amputees around the world. The company’s shares are traded on Nasdaq First North.
For more information, please.v. contact:
Carl Ekvall, CEO
Mobile: 0703 — 83 20 12
Erik Penser Bank AB is the Company’s Certified Adviser who can be reached on 08-463 8000.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Integrum AB via Globenewswire